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Summary The exact pathophysiological mechanisms responsible for gastroesophageal reflux
disease (GERD) remain unclear. Recent studies have shown that mucosal immune and
inflammatory responses, characterized by specific cytokine and chemokine profiles, may
underlie the diverse esophageal phenotypes of GERD. Interleukin 8 (IL-8), a representative
chemokine, mediates neutrophil trafficking via its receptors, mainly CXCR-1. The IL-8
mRNA and protein levels are increased in the esophageal mucosa, not only in reflux esophagitis
(RE), but also in endoscopy-negative GERD (NERD), through activation of nuclear factor-κB
(NF-κB), which is a pivotal transcription factor. Mucosal IL-8 concentrations have been
found to parallel the endoscopic severity of RE, implying that this cytokine is a key player
in the development of GERD. The mucosal levels of the C-C chemokines, macrophage
chemoattractant protein 1 (MCP-1) and regulated on activation normal T-cell-expressed and
presumably secreted (RANTES), which primarily attract monocytes and lymphocytes to the
site of inflammation, respectively, are also elevated in RE. The secreted levels of IL-8 and
IL-1β, a prototype of proinflammatory cytokine, are maximal at the proximal segment
within Barrett esophagus (BE) tissue. The expression of the two pleiotrophic proinflammatory
cytokines, IL-6 and tumor necrosis factor α, is enhanced in the intestinal epithelium of BE,
which places this epithelium at a higher risk for developing malignancy. BE is characterized by
a distinct Th-2 predominant cytokine profile (IL-4 and -10), compared to the proinflammatory
nature of RE (interferone-γ). Treatment with a proton pump inhibitor, lansoprazole reduces
the mucosal levels of IL-8 mRNA and protein in GERD, including RE and NERD. This may
occur in part through an anti-inflammatory action of proton pump inhibitors beyond gastric
acid inhibition.
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Introduction
Gastroesophageal reflux disease (GERD) is one of the most
common disorders. In the Western world, it is extremely
common; over 30% of the general population suffers from
at least monthly reflux episodes. GERD may lead to the
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development of serious complications, including ulcers,
strictures, bleeding, Barrett’s esophagus, and eventually,
adenocarcinoma of the esophagus [1–3]. It is currently
thought that reflux of gastric contents may occur as a result
of the transient relaxation of the lower esophageal sphincter
(TLESR) unrelated to swallowing or secondary peristalsis, and
that repeated episodes of reflux over time lead to impairment
of LES tone and esophageal exposure to refluxates, which
results in GERD [3, 4]. Thus, attention has been paid to the
role of injurious agents in gastric reflux, such as hydro-
chloric acid, pepsin, and bile acid, and the mechanisms by
which the esophageal epithelium fails to resist the chemical’s
adverse effect have been studied [2].
However, approximately 60% of GERD patients have no
mucosal lesions on endoscopy, 30% have reflux esophagitis
(RE), and 10% have Barrett’s esophagus [5–8]. To date, the
exact physiological mechanisms responsible for the diverse
esophageal phenotypes of GERD are poorly understood.
The frequency and duration of exposure to acid and bile, as
evaluated by 24-h monitoring, vary widely among cases of
GERD with different endoscopic findings [9–11]. Experimental
acid- and pepsin-induced esophagitis in rabbits mimics
human RE, but the degree of esophageal mucosal damage is
not correlated with the amount of reflux material [12]. Thus,
the severity and the various GERD phenotypes cannot be
predicted solely on the basis of esophageal exposure to
refluxates; this suggests that other factors are involved.
In experimental RE and in human subjects, it has been
reported that some of the substances that are considered to
be critical in the etiology of RE are classic inflammatory
products, such as prostanoids and reactive oxygen species
(ROS) [13, 14]. Moreover, recent studies have shown that
mucosal immune and inflammatory responses, characterized
by specific cytokine and chemokine profiles, may underlie
the diverse esophageal phenotypes of GERD [15–19]. In
fact, we found enhanced expression of interleukin 8 (IL-8), a
representative chemokine, in esophageal biopsy samples of
patients with non-erosive GERD (NERD), as well as RE;
the IL-8 protein levels paralleled the endoscopic severity of
RE [16, 17]. Of note, lansoprazole, a potent proton pump
inhibitor (PPI) that is widely used in Japan, decreased IL-8
expression in the esophageal mucosa of GERD patients [16,
17].
We reviewed the current data dealing with the diverse
proinflammatory cytokines implicated in the pathogenesis of
GERD. This article also provides information on the effects
of PPIs on immune and inflammatory responses that occur
through the reduction of proinflammatory cytokines.
The Involvement of Various Cytokines Located in
the Esophageal Mucosa in the Pathogenesis of
GERD
IL-8 and GERD
Chemokines are a group of cytokines with potent chemo-
tactic activity towards different populations of leukocytes; they
are involved in the pathogenesis of a variety of inflammatory
conditions. IL-8 exhibits a potent chemotactic activity for
neutrophils and plays a critical role in the induction of acute
and chronic inflammatory reactions [20, 21]. For example,
in patients with Helicobacter pylori ( H. pylori)-related
gastritis, enhanced production of IL-8 in gastric mucosa
has been reported [22]. The selective infiltration into the
esophagus of the polynuclear leukocyte subset suggests that
this chemokine plays a role in the immune and inflammatory
processes of GERD, and this is the case. Fitzgerald et al.
[15] found that, compared to subjects with noninflamed
or Barrett’s esophagus, GERD patients had significantly
higher expression levels of IL-8 messenger ribonucleic acid
(mRNA), as assessed by competitive reverse transcriptase
polymerase chain reaction (RT-PCR). Our studies have
also found that Japanese RE patients had increased relative
IL-8 mRNA expression levels, as assessed using real-time
PCR technology [17]. In addition, IL-8 protein levels
measured by enzyme-linked immunosorbent assay (ELISA)
were increased to a greater degree in the esophageal biopsy
samples obtained from RE patients compared to normal
controls [16]. The mucosal IL-8 concentrations were found
to parallel the endoscopic severity of RE (Fig. 1) [16]. Based
on immunohistochemical analysis with anti-IL-8 antisera,
IL-8 expression was found in the epithelium of esophageal
biopsy specimens (Fig. 2) [22]. In particular, GERD patients
had intense immunoreactivity against anti-IL-8 antibody. Not
Fig. 1.  The relationship between chemokine levels and endo-
scopic grading of reflux esophagitis based on the Los
Angeles classification. IL-8 levels were correlated with
the severity (grade). On the other hand, although MCP-1
and RANTES concentrations tended to be higher with
increased RE severity, the correlations were not statistically
significant. Reprinted with permission [16].H. Isomoto et al.
J. Clin. Biochem. Nutr.
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only epithelial cells but also infiltrating leukocytes showed
immunoreactivity for IL-8 antigen. In contrast, there was little
or no expression of IL-8 in normal control subjects who
were free of any histopathological abnormality. Recently, we
demonstrated that the relative IL-8 mRNA expression levels
were significantly higher in the esophageal mucosa of NERD
patients than controls [17, 19, 23]. It is of clinical importance
that IL-8 production is enhanced in such incipient GERD
patients who do not have mucosal breaks. The study also
found that NERD patients who were classified in grade M
based on the modified Los Angeles (LA) system [24] had
significantly higher IL-8 mRNA expression levels than
those classified in grade N; this highlights the immunologic
and endoscopic heterogeneity among NERD patients [23].
Collectively, IL-8, which is produced locally by esophageal
epithelium and inflammatory cells, is involved in the patho-
genesis of GERD, including NERD, and plays a role in the
development and progression of RE.
In patients with long segmental Barrett esophagus (BE),
there was a proximal-distal gradient within the BE with
respect to the IL-8 expression, as assessed by ELISA following
organ culture [18]. IL-8 levels were significantly higher in
the proximal than in the distal BE segment. In agreement
with this finding, on light microscopy, inflammation was
maximal at the new squamocolumnar junction associated
with the esophagitis. The regional variation of IL-8 expression
may be germane to the distribution of inflammatory and
malignant complications seen with BE.
The elevated levels of IL-8 mRNA and protein levels were
significantly decreased after treatment with lansoprazole in
RE and NERD patients; these patients had endoscopic
healing of the disease and cure of the reflux symptoms, which
further highlights the important role of this chemokine in the
pathogenesis of GERD [16,  17,  19]. More recently, we
conducted a long-term follow-up study dealing with the
association of IL-8 protein levels in the esophageal mucosa
with RE relapse (Fig. 3) [25]. Thirty-one outpatients with
RE, graded according to the LA classification as A or B, not
treated with any anti-secretory drugs after healing with 8
weeks of lansoprazole treatment, were enrolled in this study.
The estimated RE relapse within 3 years was 75% and
31.3% in patients with IL-8 levels greater than and less than
10 pg/mg protein, respectively. Using Cox’s proportional
hazards regression model, RE recurrence was frequently
observed in patients who had higher IL-8 levels (>10 pg/mg
protein) (odds ratio, 3.5; 95% confidence interval, 1.3–12.8,
p<0.01). These preliminary results highlight the fact that
mucosal IL-8 levels are an indicator of RE relapse.
Evidence is accumulating that chemokines exert an over-
lapping but distinct action on specific types of leukocytes by
interacting with their specific G-protein-coupled receptors
that have 7 transmembrane domains [26]. To date, CXC
chemokine receptor1 (CXCR-1) and -2 have been found
to be two distinct receptors for IL-8 [27]. It is possible
that increased IL-8 levels may facilitate trafficking of
neutrophils into the mucosa affected by GERD through IL-
8’s interaction with these receptors. Based on this hypothesis,
we studied CXCR-1 and -2 mRNA expression using RT-
PCR [28]. CXCR-1 (Fig. 4) as well as CXCR-2 mRNA
was evidently expressed in esophageal mucosa of GERD
patients. On the real-time PCR basis, in NERD patients, the
relative CXCR-1 mRNA levels, expressed as the ratio of
CXCR-1/tubulin alpha 3 (housekeeping gene) in arbitrary
Fig. 2.  Based on immunohistochemical analysis with anti-IL-8
antisera, IL-8 expression was found in the epithelium of
esophageal biopsy specimens. Reprinted with permission
[22].
Fig. 3.  Kaplan-Meier analysis: incidence of reflux esophagitis
recurrence in patients who had esophageal mucosal
interleukin 8 levels that were greater than 10 pg/mg
protein (n = 8) or less than 10 pg/mg protein (n = 23).
Reprinted with permission [25].GERD, Cytokines and Lansoprazole
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units using real-time PCR, were significantly higher than in
controls [28]. On the other hand, the relative expression
levels of CXCR-2 mRNA were comparable between GERD
patients and controls. No significant correlation was noted
between the mRNA expression levels of CXCR-1 and
CXCR-2. As shown previously, intraepithelial neutrophils, a
histopathological indicator of RE [29], were immunoreactive
for CXCR-1 in the esophageal mucosa of GERD patients
[17]. The enhanced expression of this specific IL-8 receptor
could make the affected esophageal mucosa more responsive
to locally overexpressed IL-8; thus, enhanced expression of
IL-8 and CXCR-1 could mutually encourage the trafficking
of neutrophils into esophageal mucosa [27, 30–32]. IL-8 is
regulated in an autocrine manner [33, 34]; therefore, the
interplay between IL-8 and CXCR-1 may contribute to the
amplification and protraction of inflammatory responses in
GERD. In this regard, on immunohistochemical analysis,
epithelial cells of GERD patients were found to express
abundant IL-8 antigen, and, at the same time, the epithelium
was the potential cellular source of CXCR-1 protein [17].
IL-8 exerts mitogenic actions directly or by binding to its
receptors on epithelial cells [35]. In fact, IL-8 mRNA and
protein levels are found to be associated with basal cell
hyperplasia and papillary elongation [16, 17], both of which
are histopathological hallmarks of RE [29]; these findings
support the notion that IL-8, possibly along with other
cytokines and growth factors, could contribute to esophageal
epithelial cell proliferation even in the early stage of incipient
GERD and could eventually lead to carcinogenesis. Unlike
CXCR-1, CXCR-2 is not specific for IL-8 and can bind
to other chemokines, such as growth-related oncogene α;
however, CXCR-2 has a 2- to 5-fold higher affinity for IL-8
than CXCR-1 [36]. Further research is needed to elucidate
the diverse receptor-mediated signaling pathway that is part
of the pathophysiological mechanisms of GERD.
Proinflammatory cytokines other than IL-8 and GERD
There is limited information on the possible involvement
of proinflammatory cytokines other than IL-8 in GERD
[16, 37]. In our previous work, the levels of regulated on
activation normal T-cell-expressed and presumably secreted
(RANTES) and macrophage chemoattractant protein 1
(MCP-1) in esophageal biopsy samples of RE patients were
measured [16]. In that study, the mucosal levels of RANTES
and MCP-1 were significantly higher in RE patients than in
normal controls. Though the mucosal MCP-1 and RANTES
concentrations tended to be higher with increased LA grade
severity, they were not statistically significant. RANTES
selectively regulates eosinophil trafficking [38]. In line with
this, the RANTES levels in esophageal mucosa containing
intraepithelial eosinophils were significantly higher than in
mucosa lacking the cells [16]. MCP-1, along with RANTES,
constitutes the C-C chemokine class and attracts primarily
monocytes and lymphocytes to the site of inflammation [38,
39]. It is accepted that the accumulation of mononuclear
cells in the esophageal lamina propria, but not within the
epithelium, is indicative of RE [29, 40, 41]. However, most
endoscopic biopsy samples contain small amounts of lamina
propria tissues. Thus, a proper assessment of the relationship
between mucosal production of MCP-1 and mononuclear cell
infiltration is difficult. This may also explain the discrepant
results reported by Uchiyama et al. showing that the
mucosal MCP-1 mRNA levels in RE patients were not
correlated with endoscopic RE severity [37].
Fitzgerald et al. [18], using ELISA following organ culture,
examined concentrations of Il-1β, which is a representative
proinflammatory cytokine, secreted by esophageal biopsy
samples obtained from BE patients. Similar to IL-8, the IL-
1β levels were maximal at the proximal segment within BE.
Intriguingly, pulsatile but not continuous exposure of the BE
specimens to acid and bile significantly increased expression
of IL-1β. In our study, there were no significant differences
in mucosal IL-1β levels between the RE and control groups;
however, the IL-1β levels were significantly correlated
with esophageal mucosal IL-8 production [16]. In fact, a
transcription factor nuclear factor κB (NF-κB), which regulates
gene expression of a plethora of immune and inflammatory
mediators including IL-8, IL-1β, and tumor necrosis factor α
(TNF-α) [42, 43], was found to be activated in the esophageal
mucosa of GERD patients [17]. Classically, the most common
NF-κB dimeric complexes are the p65-p50 heterodimers
or the p50 homodimers [42, 43]. The NF-κB dimers are
sequestered in the cytoplasm in an inactive form by their
association with inhibitory κB (I-κB). Following cellular
stimulation by proinflammatory cytokines such as IL-1 and
TNF-α, reactive oxygen species, and microbial infection,
multiple kinase cascades lead to the phosphorylation of I-κB
and its subsequent degradation; this allows NF-κB to
become active and then translocate into the nucleus [42–44].
Fig. 4.  The CXCR-1 mRNA transcripts were detected as 257 bp
band using the reverse transcriptase polymerase chain
reaction. Each lane represents the following: 1; asymp-
tomatic normal control, 2; endoscopy-negative GERD
patient, 3–5; reflux esophagitis patients, 6; non-template
negative control and 7; positive control.H. Isomoto et al.
J. Clin. Biochem. Nutr.
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In line with this, p65 and p50 subunit immunoreactivities were
mainly observed in the nuclei of epithelial cells of GERD
patients, whereas the dimeric proteins were expressed at
lower levels in the epithelium of asymptomatic controls [17].
We also demonstrated colocalization of activated NF-κB
with the expression of IL-8, which indicates a functional role
for this transcription factor [17]. Accordingly, the following
changes likely take place within the esophageal mucosa of
GERD: (1) activation and translocation of NF-κB to the nuclei
of epithelial cells possibly in response to proinflammatory
cytokines and/or direct stimulation by gastroduodenal
refluxates; (2) up-regulation of IL-8 mRNA induced by
the activated NF-κB system; and (3) local overexpression
of the IL-8 protein.
Epithelial expression of TNF-α, as well as its receptor
TNFR1, was up-regulated during the progression of BE
to adenocarcinoma, based on immunohistochemistry and
Western blot analysis findings [45]. In contrast, a low
expression level was present in inflamed and non-inflamed
squamous epithelium. Unexpectedly, in Barrett’s adeno-
carcinoma cells, TNF-α induced transcription of an oncogene,
c-myc, via a β-catenin mediated pathway that is independent
of NF-κB [45].
Th 1/Th 2 cytokine profile and GERD
Recent studies have shown that expression of interferon γ
(IFN-γ), which is a representative Th 1 cytokine, as assessed
by semi-quantitative RT-PCR methodology, was markedly
increased in esophageal biopsy samples obtained from RE
patients compared those from non-inflamed squamous
mucosa or BE patients; there was a modest increase in anti-
inflammatory IL-10 expression and no increase in IL-4
expression [15]. On the other hand, in BE mucosa, the
expression of IFN-γ was similar to that seen in non-inflamed
squamous mucosa; however, in BE mucosa, the expression of
Th-2 cytokines IL-10 and IL-4 was significantly increased
compared to unaffected squamous esophagus or RE mucosa.
Thus, in contrast with the proinflammatory nature of RE, BE
is characterized by a distinct Th-2 predominant cytokine
profile [15]. Furthermore, the proportion of Th 2 effector
cells (plasma cells and mast cells) was higher in esophageal
biopsy specimens obtained from BE patients than from RE
patients [46]. On immunohistochemistry, most plasma cells
in BE and RE samples expressed IgG, but several IgE-
positive plasma cells were detected in BE samples; these
were rare in RE. In addition, isolated lymph follicles were
commonly observed in BE patients, but not in RE patients.
Thus, in BE, the inflammatory response is skewed towards a
more pronounced humoral immune response [46].
IL-6, a pleiotropic cytokine associated with a Th 2
response, can be involved in malignant transformation and
tumor progression [47]. Dvorakova et al. [48], using ELISA,
reported that increased IL-6 levels were secreted from
BE tissue in conditioned media compared with squamous
mucosa; on immunohistochemical analysis, this cytokine was
found to be expressed in intestinal glandular epithelium in
BE tissue. The activation of signal transducer and activator
of transcription 3 was observed, with subsequent increased
expression of anti-apoptotic genes, such as myeloid cell
leukemia 1 and Bcl-xL. These data suggest a prominent role
for IL-6 in the development of BE and in apoptotic resistance.
This places BE epithelium at higher risk of developing
malignancy.
Lansoprazole Treatment and Proinflammatory
Cytokines in GERD
In GERD patients, several reports have described the effects
of lansoprazole treatment on expression levels of diverse
proinflammatory cytokines. Using ELISA, we examined IL-
8, MCP-1, RANTES, and IL-1β level changes in NERD
patients’ esophageal mucosa after 8 weeks of lansoprazole
therapy [16, 17, 19]. Pretreatment IL-8 concentrations were
significantly decreased compared to posttreatment levels
[16]. Furthermore, real-time PCR analysis revealed IL-8
mRNA expression levels were significantly reduced after 8-
week lansoprazole therapy in NERD patients [17]. Similarly,
Yoshida et al. [19] reported that lansoprazole significantly
decreased both IL-8 mRNA and protein levels in GERD
patients, including the range of patients from NERD to RE.
To date, there have been no data published on the effects of
PPIs other than lansoprazole on esophageal expression of
proinflammatory cytokines in human GERD.
There are several animal GERD models, primarily involving
rats. In a rat chronic acid RE model, RE was induced by
ligating the transitional region between the forestomach and
the glandular portion and then wrapping the duodenum
near the pylorus with a catheter; using this model and real-
time PCR, Fujiwara et al. [49, 50] analyzed the expression
and dynamics of IL-1β, TNF-α, MCP-1, macrophage
inflammatory protein 1α (MIP-1α), MIP-2, and GRO/
cytokine-induced neutrophil chemoattractant-2α (CINC-
2α), which corresponds to IL-8 in humans. The mRNA
expression levels of each proinflammatory cytokine were
significantly increased in the esophageal lesions compared
to normal esophagus. In regions with esophagitis, numerous
inflammatory leukocytes were present in the lamina propria,
and, on immunochemistry, the submucosal layer had positive
reactions for these cytokines, and the endothelial cells
stained intensely for ICAM-1. The numbers of leukocyte
function-associated antigen 1 (LFA-1) and CD11b/CD18-
positive cells were significantly increased in rats with chronic
esophagitis. These results demonstrate the importance of
proinflammatory cytokines and adhesion molecules in the
pathogenesis of rat chronic RE. In this model, treatment
with the PPI rabeprazole almost completely inhibited theGERD, Cytokines and Lansoprazole
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development of RE and significantly decreased the expression
of cytokines [50]; this suggests that gastric acid reflux
may play a role in the induction of chronic esophageal
inflammation. In a rat acute RE model, which was induced
by inserting a caliber ring into the duodenum, treatment with
ranitidine, a histamine-2 receptor antagonist (H2RA), did
not affect the severity of the macroscopic and microscopic
appearance of the experimentally induced esophagitis [51].
However, compared to ranitidine treatment, a novel anti-
oxidant agent, DA-9601, markedly attenuated the gross
esophagitis and the histological degree of esophageal
inflammation [51]. In addition, in a rat chronic gastro-
duodenal reflux model, in which a esophagogastroduodenal
anastomosis was generated between the jejunum and the
gastroesophageal junction, rabeprazole and nizatidine, the
H2RA, did not affect the severity of mucosal hyperplastic
scores or the histological parameters of esophagitis [52]. In
contrast, treatment with a protease inhibitor, camostat mesilate,
was associated with a significant decrease in mucosal hyper-
plastic and inflammatory scores, and the enhanced expression
of CINC-1, another IL-8-like chemokine [37,  49] in
inflamed esophageal mucosa, which was induced by the
combined refluxates, was markedly inhibited in the camostat
mesilate-treated group [52]. Thus, not only gastric acid but
also duodenal contents, including pancreatic proteases, are
involved in esophageal immune and inflammatory responses
through locally enhanced production of proinflammatory
mediators. In vitro, bile acid deoxycholic acid, even at neutral
pH, induces IL-8 expression in Barrett’s adenocarcinoma
OE 33 cells through activation of NF-κB; this is linked to
transduction of downstream survival factors [53], which
suggests that a PPI given alone may not be able to prevent
the progression of Barrett’s epithelium to cancer.
Nevertheless, evidence is accumulating that highlights the
anti-inflammatory action of PPIs, such as lansoprazole and
omeprazole, which is independent of gastric acid inhibition
[54–56]. In fact, lansoprazole treatment suppresses the
induction of proinflammatory cytokines (IL-1β, TNF-α, and
IL-6) in murine peritoneal macrophages lacking P-type AT-
Pase [56]. More recently, it has been shown that exposure to
either PPI results in a strong induction of heme oxygenase-1,
which has a central role in cellular antioxidant defenses and
exerts anti-inflammatory actions [57–59] at both the mRNA
and protein levels; this leads to an increased activity of this
enzyme in gastric and endothelial cells [55]. It is unknown
whether PPIs can induce heme oxygenase-1 in esophageal
cells in vitro and in vivo; however, it is tempting to speculate
that the improvement in esophageal immune and inflammatory
responses seen with PPI treatment may be in part mediated
by beneficial anti-inflammatory effects that go beyond acid
suppression [55, 60]. Further studies are warranted to establish
new therapeutic avenues for PPI treatment in preventing
inflammatory disorders, including GERD.
Conclusions
Diverse proinflammatory cytokines are associated with
the development and progression of GERD. In particular, a
chemokine, IL-8, produced in esophageal mucosa plays a
pivotal role in the pathogenesis of GERD including NERD
through its specific receptor. Mucosal IL-8 levels are correlated
with endoscopic RE severity and provide information about
the risk of disease relapse. Other chemokines, such as
RANTES and MCP-1, are also involved in RE pathogenesis.
The BE-dysplasia –carcinoma sequence may be regulated by
the overexpression of proinflammatory cytokines, such as
IL-1β, TNF-α, and IL-6. BE is characterized by a Th-2
predominant cytokine profile, in contrast to the Th-1 nature
of RE. Lansoprazole treatment reduces the mucosal levels of
IL-8 expression in human GERD. This may occur in part
through anti-inflammatory actions of PPIs, independent of
gastric acid suppression.
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